1. Mexico Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Genomma Lab Internacional SAB de CV Class B

Genomma Lab Internacional SAB de CV Class B

0.62
EUR
0.00
(0.00%)
723.54MMarket Cap
Feb 24Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
10.83
11.01
10.7
11.54
12.68
11.52
12.55
13.71
15.37
16.93
17.2
19.03
17.94
- -
Basic EPS, GAAP
1.67
1.38
-1.04
-1.71
1.34
1.08
0.74
1.39
1.3
1.4
1.07
1.53
1.65
- -
Free Cash Flow per Basic Share
-0.82
0.13
1.03
1.35
1.13
0.05
0.13
1.69
1.25
2.05
2
2.18
2.07
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
0.39
0.78
0.61
0.8
0.8
0.6
Book Value per Share
8.31
9.81
8.57
6.28
6.53
6.6
7.12
8.69
10.04
10.53
9.9
11.13
11.37
12.04
Tangible Book Value per Share
1.77
2.5
1.87
1.34
1.59
1.75
2.3
3.87
4.89
5.1
4.58
4.98
5.56
6.34
Basic Weighted Avg Shares
1,049
1,048
1,032
981
952
1,024
1,013
1,012
1,008
993
957
978
978
977
Sales/Revenue/Turnover
11,361
11,541
11,042
11,316
12,078
11,794
12,713
13,870
15,487
16,820
16,467
18,607
17,541
- -
Operating Margin (%)
25.8
21.08
-0.62
1.68
20.69
18.54
17.89
21.15
19.35
19.64
19.44
20.99
21.41
- -
Depreciation Expense
64
98
118
84
70
81
142
159
170
227
227
360
379
- -
Net Income, GAAP
1,752
1,445
-1,069
-1,681
1,279
1,109
750
1,404
1,308
1,389
1,026
1,493
1,614
- -
Effective Tax Rate (%)
30.51
29.45
- -
- -
35.04
37.09
51.49
35.33
41.14
38.84
36.95
27.67
33.68
- -
Profit Margin (%)
15.43
12.52
-9.68
-14.85
10.59
9.41
5.9
10.12
8.44
8.26
6.23
8.02
9.2
- -
Working Capital
6,833
9,542
5,043
2,696
1,536
4,512
4,139
5,424
4,950
1,956
3,997
5,528
5,699
6,008
LT Debt
4,651
6,505
5,829
3,760
1,690
5,197
4,531
4,475
3,856
1,590
4,234
5,113
4,796
4,566
Total Equity
8,835
10,503
9,249
6,793
7,049
6,718
7,249
8,842
10,072
10,153
9,383
10,885
11,118
11,776
Return on Invested Capital (%)
17.24
11.42
- -
- -
14.87
13
9.3
12.78
11.52
12.2
12.77
18.02
14.59
- -
Return on Capital (%)
15.36
10.32
- -
- -
12.03
11.98
8.05
11.87
10.01
10.49
9.62
12.94
11.86
- -
Return on Common Equity (%)
22.36
15.2
-11.08
-21.59
19.05
16.36
10.73
17.44
13.83
13.74
10.51
14.73
14.67
- -

Capital Structure

MXN

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,832
3,329
3,206
LT Borrowings
4,770
4,729
4,566
LT Finance Leases
26
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
978
978
978
Market Capitalization
16,948
17,309
14,442

Working Capital

MXN

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
12,845
13,661
13,195
Cash, Cash Equivalents & STI
3,054
2,809
2,435
Accounts Receivable, Net
4,496
5,255
5,373
Inventories
1,840
1,941
1,955
Total Current Liabilities
7,145
7,652
7,187
Payables & Accruals
- -
- -
- -
ST Debt
2,832
3,329
3,206
Deferred Revenue
- -
- -
- -

Growth Rates

MXN

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.77%
5.06%
2.14%
Free Cash Flow
131.61%
7.16%
-4.85%
Net Income, GAAP
-5.04%
5.37%
8.1%
Sales/Revenue/Turnover
4.92%
5.09%
-5.73%
Total Cash Common Dividend
- -
- -
0.38%

Quarterly Revenue

MXN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,197
4,651
5,093
4,666
18,607
2025
4,406
4,676
- -
4,017
17,541
2026
4,191
4,397
- -
- -
- -

Quarterly Earnings Per Share

MXN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.39
0.67
0.7
-0.17
1.53
2025
0.51
0.36
- -
0.33
1.65
2026
0.51
0.38
- -
- -
- -

Quarterly Dividends Per Share

MXN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.2
0.22
0.21
0.19
0.8
2025
0.2
- -
- -
0.2
0.8
2026
0.2
0.2
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Marco Sparvieri
Full Time Employees
1,465
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Av. Antonio Dovalí Jaime no.70 Mexico City DF Mexico 01210
IPO Date
Jun 16, 2008
Website
genommalab.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Genomma Lab Internacional, S.A.B. de C.V. (LABB.MX) develops, manufactures, markets and sells a broad portfolio of branded over-the-counter (OTC) pharmaceutical and personal care products primarily in Mexico, the United States and Latin America; core offerings include anti-acne treatments such as Asepxia, analgesics including Tafirol paracetamol and newly acquired IBU 400 ibuprofen, isotonic beverages like Suerox alongside Suero Repone and Suero Oral, gastro products such as Treg omeprazole, anti-flu remedies, antacids, anti-ulcer treatments, hemorrhoid and varicose vein therapies, ophthalmic medications, infant nutrition, dandruff shampoos, hair loss prevention products, muscle pain ointments, antifungal treatments, stress relief products, anti-wrinkle creams, soaps, razors and self-diagnosis kits, among over 50 brands distributed through more than 500,000 points of sale across 18 countries. The Mexico City-based company, founded in 1996, generates approximately 48% of net sales from Mexico, 42% from Latin America and 10% from the USA, with operations through subsidiaries in the United States, Peru, Chile, Ecuador and Honduras. In July 2024, Genomma Lab completed strategic bolt-on acquisitions of four brands—Suero Repone and Suero Oral in the USA to bolster its isotonic beverage presence in the Hispanic market, and IBU 400 and Treg in Argentina to expand into ibuprofen analgesics and strengthen gastro categories—for a total investment of US$25.6 million, leveraging local cash and debt; earlier in 2024, the company divested its stake in distributor Marzam, issued LAB 25 and LAB 25-2 unsecured bonds totaling MXN1.2 billion, announced multiple dividend payments and saw its pharma manufacturing facility receive pending GMP certification for the Mexican market.

Company News

Company News APIChatGPT

  • prnewswire.com

    Genomma Lab Internacional Announces Results for the Third Quarter 2026

  • seekingalpha.com

    Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Q2 2026 Earnings Call Transcript

  • seekingalpha.com

    Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Q1 2026 Earnings Call Transcript

  • prnewswire.com

    Genomma Lab Internacional Announces Results for the First Quarter 2026

  • prnewswire.com

    Genomma Lab Internacional S.A.B. de C.V. First Quarter 2026 Earnings Results Conference Call

  • seekingalpha.com

    Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Q4 2025 Earnings Call Transcript

  • prnewswire.com

    Genomma Lab Internacional Announces Results for the Fourth Quarter and Full Year 2025

  • prnewswire.com

    Genomma Lab Internacional S.A.B. de C.V. Fourth Quarter 2025 Earnings Results Conference Call

  • prnewswire.com

    GENOMMA LAB INTERNACIONAL ANNOUNCES FOURTEENTH DIVIDEND PAYMENT

  • prnewswire.com

    GENOMMA LAB INTERNACIONAL ANNOUNCES FOURTEENTH DIVIDEND PAYMENT

  • seekingalpha.com

    Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Q3 2025 Earnings Call Transcript

  • prnewswire.com

    Genomma Lab Internacional Announces Results for the Third Quarter 2025

  • prnewswire.com

    Genomma Lab Internacional S.A.B. de C.V. Third Quarter 2025 Earnings Results Conference Call

  • prnewswire.com

    Genomma Lab Internacional Announces Results for the Second Quarter 2025

  • prnewswire.com

    GENOMMA LAB INTERNACIONAL ANNOUNCES TWELFTH DIVIDEND PAYMENT

  • prnewswire.com

    GENOMMA LAB INTERNATIONAL INFORMS TOTAL PREPAYMENT OF "LAB 23" UNSECURED LOCAL BOND (CEBUR)

  • prnewswire.com

    Genomma Lab successfully issued the LAB 25 and LAB 25-2 unsecured bonds (Cebures) for a total amount of $1.2 billion pesos, which will be used to prepay liabilities, including the full early amortization of the LAB 23 bond

  • prnewswire.com

    Genomma Lab Internacional Announces Results for the First Quarter 2025

  • prnewswire.com

    Genomma Lab Internacional S.A.B. de C.V. First Quarter 2025 Earnings Results Conference Call

  • prnewswire.com

    GENOMMA LAB INTERNACIONAL ANNOUNCES ELEVENTH DIVIDEND PAYMENT